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Abstract
In the management of head and neck cancer, radiotherapy is usually a coadjuvant to surgery, or is applied on a 
palliative basis. The most important complication of such radiotherapy is osteoradionecrosis, which manifests as 
an area of exposed necrotic bone in the maxillae or mandible that fails to heal during at least three months. In most 
cases osteoradionecrosis gradually progresses, becoming more extensive and painful, and its late manifestations 
comprise infection and pathological fracture.
The present study provides a literature review and update on the risk factors underlying osteoradionecrosis, its 
clinical and diagnostic particulars, prevention, and most widely accepted treatment options, as well as new possi-
bilities relating to clinical management of the disorder. Lastly, a new early management protocol is proposed based 
on the current consensus criteria relating to maxillary osteonecrosis secondary to treatment with bisphosphonates, 
together with the adoption of new therapies supported by increased levels of evidence.
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Introduction
Osteoradionecrosis (ORN) of the maxillae is the most se-
rious and important complication of radiotherapy (RT) 
administered in patients for head and neck tumors. RT is 
usually prescribed as adjuvant therapy following onco-
logical surgery; however, it can be administered together 
with chemotherapy or as palliative treatment (1).
Osteoradionecrosis is defined as an area of exposed 
necrotic bone in one or more locations of the maxillary or 
mandibular alveolar process, with failure to heal during 
at least three months. ORN can develop spontaneously in 
one-third of all cases, but usually manifests after tooth 
extraction, after oral surgery, or due to irritation caused 
by poorly fitting dentures. In most cases the condition is 
chronic, progresses gradually and becomes more exten-
sive and painful (2,3).
Marx (3) defined ORN as resulting from the effects of 
RT, i.e., hypovascularization, hypoxia and hypocellu-
larity – these circumstances in turn adversely affecting 
tissue repair capacity. At present a fibro-atrophic mecha-
nism has been suggested, characterized by alterations 
in bone metabolism and the formation of free radicals, 
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inflammation and microvascular thrombosis that evolve 
towards necrosis of the affected tissues (4).
Clinically, ORN remains latent and without symptoms 
until the lesions are visually detected or the patient be-
gins to experience discomfort, with denuded bone, pain, 
swelling, suppuration and the formation of a cutaneous 
fistula or pathological fracture (5).
Treatment must aim to eliminate the pain, control in-
fection and avoid or reduce the spread of ORN. Con-
servative management is recommended in the early 
stages, and classically comprises antibiotics, antisep-
tics and hyperbaric oxygen therapy (HBO) – the latter 
currently being the subject of considerable controver-
sy (6). Surgery has been used in more evolved stages 
of ORN, characteri-zed by extensive osteolytic areas, 
sequestration, cutaneous fistulas or pathological frac-
tures. Ablation surgery of the lesion is first carried out, 
followed by reconstructive surgery (7,8). In the most ad-
vanced phases it proves more difficult to treat and contain 
progression of the lesions.
Based on a literature review, the present study proposes a 
new clinical systematization of ORN, placing priority on 
prevention and early treatment of the lesions, with a view 
to securing the most effective management possible. In 
turn, new treatment modalities for ORN are presented.
Literature Review
-Etiopathogenesis and risk factors
Radiotherapy appears to cause ORN because it affects the 
small blood vessels of bone, inducing inflammation (en-
darteritis), which favors the generation of small thrombi 
that obliterate the vascular lumen and thus interrupt ti-
ssue perfusion (Figure 1). Likewise, RT produces an in-
crease in free radicals and alters collagen synthesis. The 
bone loses its normal cellularity and undergoes fibrosis-
atrophy with impairment of its repair and remodeling ca-
pacity (4). Under such conditions even minimal external 
trauma causes ulceration, facilitating contamination and 
infection, and thus favoring bone necrosis. According to 
Marx (3), progressive hypoxia, hypovascularization and 
hypocellularity are observed in the affected bone. Howe-
ver, this metabolic-pathological situation is influenced 
by a range of triggering and risk factors that have been 
identified and described in the literature (4,5,9). In ge-
neral, the risk factors may be related to the tumor, the 
patient, or the radiotherapy provided.
The tumor-dependent factors fundamentally comprise 
the anatomical location of the growth, the nearness or 
degree of involvement of neighboring bone structures, 
and the tumor stage and size. The patient-dependent 
factors in turn particularly refer to post-radiotherapy 
extractions and oral surgery such as osteotomy or man-
dibular resection, performed before RT. In fact, ORN 
without prior surgery has been shown to be extremely 
rare (2.7% incidence after 5 years). Other influencing 
factors are the presence of periodontitis, poor oral hy-
giene, and previous irradiation of the field (10).
Alcohol consumption and smoking are very important 
clinical factors, and are much more deleterious in the 
context of ORN than in maxillary osteonecrosis due to 
treatment with bisphosphonates, as described by Bagán 
et al. (11).
Lastly, the radiotherapy-dependent risk factors are the 
total dose delivered (with increased effects at >65 Gy), 
dose fractionation, the type of RT used (brachytherapy 
or external irradiation), and the size of the irradiated 
area. All these factors capable of increasing the inci-
dence of ORN must be taken into account in order to 
prevent the development of such lesions (12).
-Clinical and diagnostic considerations
The symptoms of ORN can manifest months or years 
after irradiation of the patient. In some cases the lesions 
are discovered in the course of visual inspection of the 
oral cavity, or due to discomfort experienced in a given 
area of the mouth. The most commonly affected location 
is the mandible (80%), and in the premolar and molar 
regions. This appears to be attributable to the increased 
bone density in these zones, and to their scant collateral 
circulation compared with the upper maxilla (13). 
The lesions manifest as an ulceration, with the exposure 
of rough and necrotic bone. While clinically the lesions 
appear small, imaging techniques such as computed 
tomography (CT) reveal a larger lesion size (2). Over-
infection in turn causes pain, and patients may experi-
ence dysesthesia in certain zones, as well as chewing or 
swallowing difficulties (13). The impacting of food in 
the lesions can give rise to intense halitosis.
The disease tends to take a chronic and progressing 
course, alternating periods without symptoms and pe-
riods characterized by pain – particularly when the le-
sions become overinfected. The symptoms depend on 
the location and extent of bone damage (14). In more 
advanced stages of ORN it is possible to observe bone 
sequestration, trismus, intense pain, swelling, cutane-
ous fistulas and pathological mandibular fractures.Fig. 1. Algorithm of osteoradionecrosis physiopathology.
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The diagnosis is usually based on the clinical findings 
and on the patient history, with confirmation being 
provided by the radiological study and biopsy findings 
(1-3). The imaging techniques used to assess the extent 
of osteolysis comprise panoramic X-rays and CT (15).
ORN and bisphosphonate-induced maxillary os-
teonecrosis may be clinically indistinguishable in the 
absence of knowledge of the patient antecedents. Nev-
ertheless, Bagán et al. (11), in a study of 20 cases of 
ORN and 53 cases of maxillary osteonecrosis, reported 
a series of important differences. Firstly, males were 
more often affected than females in situations of ORN 
compared with bisphosphonate-induced maxillary os-
teonecrosis (80% versus 37.7%), and toxic habits such 
as alcohol abuse and smoking had a greater influence in 
ORN (smoking 60%, alcohol 40%). Likewise, sponta-
neous presentations were more frequent in ORN (50%), 
and the incidence of mandibular fractures (20%) and 
cutaneous fistulas (35%) was also greater in ORN.
-Prevention
Preventive measures must be evaluated with a view to 
reducing the risk or severity of ORN. Deficient dental hy-
giene and septic mouth have been shown to increase the 
risk of osteoradionecrosis. Likewise, ORN is three times 
less frequent in edentulous patients than in patients who 
retain their teeth, possibly as a result of the trauma asso-
ciated with the need for extractions after irradiation, and 
the greater number of germs present (16).
Before treatment, a thorough dental exploration is indi-
cated, evaluating those teeth with a poor prognosis due 
to caries, periodontal disease, or with latent infections 
(17). Repair should be limited to those teeth that are 
truly amenable to restoration and which have adequate 
chances for survival. In these cases extractions should 
be made at least 2-3 weeks before RT. In the case of re-
tained teeth, this period should be even longer (18).
Another important consideration after RT for lessening 
the risk of ORN is good fitting, support and stability of 
removable dentures, avoiding points of excessive pres-
sure that may give rise to pressure ulcers.
-Therapeutic considerations
To date, the clinical management of ORN has been 
complex and unsatisfactory. Conservative treatment 
can be considered in the early stages, when ORN is 
characterized by a single small lesion. In such situations 
involving a localized and early-stage lesion, local care 
and medication (antibiotics) can resolve over half of all 
cases (17). However, more aggressive surgical treatment 
is required in more advanced stages.
A separate question is the advisability to use or not use 
hyperbaric oxygen therapy, the results of which have 
been the center of considerable controversy and debate. 
Since its use was suggested for treating ORN, the re-
sults of hyperbaric oxygen therapy appear to have been 
contradictory and scantly convincing (5). The tech-
nique involves oxygen perfusion of the tissues, which 
exerts a stimulatory effect upon repair processes such 
as osteogenesis. In addition, hyperbaric oxygen therapy 
improves angiogenesis by increasing the expression of 
growth factors such as vascular endothelial growth fac-
tor (VEGF). However, overinfection with Actinomyces 
can worsen these conditions (5,6).
Based on the studies published to date, it seems that the 
inconveniences of hyperbaric oxygen therapy outweigh 
its advantages. In advanced or refractory cases of ORN, 
only surgical treatment can be prescribed. In addition, 
oxygen therapy must be avoided when tumor recurrence 
or residual tumor tissue is suspected (6). Some authors 
only recommend the technique in the case of important 
infection, or when using vascularized free grafts (5).
Medical treatment must be provided early in order to 
secure good results, at a time when the lesions are still 
asymptomatic and stable. Irrigation of the lesion with 
an antiseptic such as chlorhexidine is indicated at this 
point, with improvements in oral hygiene and the pos-
sibility of performing careful curettage or debridement 
of the exposed area. The pain is treated with analgesics, 
and antibiotic use is indicated in the case of lesion over-
infection. In the presence of important infection, culture 
and an antibiogram are indicated, though broad spec-
trum treatment with amoxicillin / clavulanic acid and 
fluoroquinolone has yielded good results (5). Chronic 
secondary infection with Actinomyces is refractory to 
treatment.
When the lesions are extensive and important, with per-
sistent pain, trismus, involvement of the internal corti-
cal layer, cutaneous fistulas or pathological fractures, 
surgery is required in order to remove all the affected 
tissue, followed by reconstructive surgery in a later 
stage (5).
The greatest advances in the surgical management of 
ORN have been made in reconstructive surgery, repla-
cing the necrotic bone with bone grafts and a regional 
vascularized flap or with free grafts capable of restoring 
mandibular continuity with adequate bone volume and 
quality, sufficient crest height and integrity of the soft 
tissues (17).
-New therapeutic possibilities
New treatment possibilities have recently been proposed, 
though not all of them are supported by the desirable 
level of scientific evidence. In this context, ultrasound 
has been suggested with the purpose of promoting an-
giogenesis, with a direct vasodilatory effect, inducing 
the synthesis of proteins and cytokines, and stimulating 
the production of nitrous oxide and prostaglandin E2 on 
the part of the osteoblasts and fibroblasts (5).
Likewise, techniques such as bone distraction have been 
proposed to repair previously resected areas, inducing 
progressive expansion of quality bone and neovascu-
larization in the zone (19).
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In turn, the use of certain biomolecules has been sug-
gested with the aim of directly inducing osteogenesis 
and thus regenerating the affected areas. These mole-
cules comprise bone growth factors such as bFGF and 
morphogenetic proteins such as bmp-1 and rhbmp2 (5). 
However, the studies have been carried out in animal 
models, without clinical trials or acceptable levels of 
evidence.
Of all the new therapeutic models, the application of 
antioxidant agents has offered the best results to date, 
in the context of controlled clinical trials. Of these 
antioxidant agents, pentoxifylline (PTX) derived from 
methylxanthine produces an anti-tumor necrosis factor-
alpha effect, facilitates microcirculation, and inhibits 
the inflammatory mechanisms, fibroblast proliferation 
and the formation of extracellular matrix (20).
Tocopherol (vitamin E) protects the cell membrane 
against peroxidation, and partially inhibits expression 
of the procollagen gene and TGF-β1 (20).
A synergic effect has been observed between PTX and 
tocopherol in the treatment of ORN. These are moreo-
ver accessible, well tolerated and safe drugs.
Delanian et al. (20), in the context of prolonged treat-
ment (mean = 16±9 months) of 54 patients with ORN in-
volving a PTX dose of 800 mg/day and vitamin E 1000 
IU/day (5 days a week), recorded an 89% reduction in 
bone exposure after 12 months, and an even greater re-
duction over longer periods of treatment.
Discussion
Osteoradionecrosis (ORN) is characterized by delayed 
bone repair secondary to damage caused by radiothe-
rapy (RT). The mean incidence of the disorder is 10%, 
and it is particularly seen after traumatisms in the form 
of dental extractions – manifesting between 6 months 
and 5 years after radiotherapy (90% of the lesions being 
located in the mandible) (3).
The clinical management of ORN is difficult and nor-
mally comprises medical care, the avoidance of toxic 
habits, improvement of dental hygiene, the control of 
infections with antibiotics and antiseptics, and removal 
of the necrotic tissue with more aggressive surgery once 
complications have appeared (pathological fractures).
In addition, many clinical guides mention the possibi-
lity of employing hyperbaric oxygen therapy as a coad-
juvant measure, though its use is controversial (6).
In any case, no general consensus-based clinico-the-
rapeutic protocol has been established to deal with this 
serious disorder, despite the experience gained in a simi-
lar (though not identical) clinical situation in the form of 
maxillary osteonecrosis secondary to bisphosphonate 
therapy. Ruggiero et al. in 2006 (21), and Bagán et al. 
(22) in 2009, proposed a new clinical classification for 
maxillary osteonecrosis, based on three evolutive stages 
– the second stage being subdivided into two substages 
according to whether the discomfort improves with an-
tibiotic treatment or not. This classification has the ad-
vantage of establishing clinical stages that help define 
more effective treatment strategies, and on the basis of 
the literature review carried out in this study, it could be 
used for the management of RT-induced ORN.
The aim is to diagnose the condition in the earliest stage 
possible. Knowing that the patient has undergone radio-
therapy, we should be alerted to detect bone exposure or 
excessively prolonged socket healing when conducting 
posterior controls or when having to perform extrac-
tions. An early diagnosis is important, since what was 
previously taken to represent the classical manifesta-
tion of ORN (intense pain, swelling, cutaneous fistula 
or fracture) is presently considered to represent a very 
advanced stage of the disease.
Thus, as suggested by some authors, it is very important 
to diagnose the condition in the first days of bone ex-
posure (5,17) – this being the ideal moment for starting 
treatment (Table 1).
In the early stage of ORN all mucosal irritants should be 
suppressed (smoking, alcohol, dentures), oral hygiene 
should be optimized, and 0.2% chlorhexidine rinses 
should be applied to the lesions 3-4 times a day.
Controlled clinical trials are needed to assess the effi-
cacy of PTX and vitamin E treatment during this early 
period (20).
In a second stage, when pain develops, the above mea-
sures should be continued, though adding antibiotics 
such as amoxicillin / clavulanic acid and ciprofloxacin. 
Once the discomfort has disappeared, the same mea-
sures as before are resumed. However, if the pain and 
discomfort persist, minor surgical interventions can be 
carried out, such as curettage of the lesion margins or 
debridement of the exposed area, provided the lesions 
are small (< 1 cm in the anterior zone and < 0.5 cm in 
posterior sectors) and osteolysis does not reach the ex-
ternal cortical layer (17).
In a third stage, when infection becomes continuous 
or the extent of osteolysis is considerable, pain proves 
intense, or fistulization and suppuration or fractures oc-
cur, more radical ablation surgery is needed to remove 
the entire osteolytic zone, leaving vital and vascula-
rized bone margins. Posteriorly, reconstructive surgery 
can be carried out using pediculate or vascularized free 
grafts with bone grafting (5,17). Although the treatment 
of ORN is complex, widely accepted criteria should be 
established to reduce the advanced complications of os-
teoradionecrosis and improve the quality of life of these 
patients. 
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